Oncology

News

J&J says two drugs are better than one in pretreated myeloma

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.

Oncology

Beyond traditional cancer treatment: Can we confront unmet n...

Surgery, chemotherapy, radiotherapy, and immunotherapy are designed to kill cancer, but what if we could control cancer?

News

NHS starts first national rollout of Blenrep for myeloma

England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.

News

BioNTech to buy rival mRNA firm CureVac for $1.25bn

BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.

News

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.

News

BMS' radiopharma unit builds with $1.35bn Philochem deal

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

J&J says two drugs are better than one in pretreated myeloma

Beyond traditional cancer treatment: Can we confront unmet n...

NHS starts first national rollout of Blenrep for myeloma

BioNTech to buy rival mRNA firm CureVac for $1.25bn

FDA clears Nuvation's first product Ibtrozi, for lung cancer

BMS' radiopharma unit builds with $1.35bn Philochem deal

AI specialists Enveda and Basecamp rake in the cash

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks